New Oral Antibiotic Works Against Drug-Resistant Gonorrhea

10 June 2024

Medscape Logo

10 June 2024 

A first-in-class antibiotic zoliflodacin is non-inferior to standard of care (SOC) in the treatment of uncomplicated gonorrhea and also shows activity against resistant forms of the infection, a phase 3 clinical trial has shown.

The single-dose oral suspension also had a high microbiological cure rate at urogenital and extragenital sites of infection, and safety was comparable with the standard treatment of ceftriaxone plus azithromycin.

The study was carried out by the nonprofit Global Antibiotic Research and Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, providing the first example of a successful public-private partnership in the development of a critically needed antibiotic.